Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sB24M in Severe Pyoderma
NCT04895566Phase 1Completed
- Sponsor
- SWISS BIOPHARMA MED
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sB24M in pyoderma gangrenosum (PG) and pyoderma vegetans, sponsored by SWISS BIOPHARMA MED. Primary endpoint: Objective Response Rate at 1 year. Started May 2021; status: completed.
02
Drugs
sB24M
03
Conditions
pyoderma gangrenosum (PG)pyoderma vegetans
Beyond the preview
Go deeper on NCT04895566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895566.